Molecular heterogeneity of factor XI deficiency in Tunisia

Factor XI (FXI) deficiency is a rare inherited bleeding disorder that is highly prevalent in Ashkenazi Jewish ancestry but sporadically observed in most ethnic groups. It is heterogeneous both in clinical presentation and in genetic causality. Although a large spectrum of mutations associated with this disorder has been reported in several populations, genetic data of FXI deficiency in Tunisia are poorly described. The purpose of this study was to determine the molecular basis of FXI deficiency among Tunisian patients. Fourteen index cases from nine unrelated families with FXI deficiency, referred to Hemophilia Treatment Center of Aziza Othmana Hospital, were included in this study. The patients’ F11 genes were amplified by PCR and subjected to direct DNA sequencing analysis. Sequencing analysis of F11 genes identified three distinct mutations; the Jewish type II nonsense mutation E117X, one previously reported missense mutation E602Q and one novel missense mutation V271M, which led to the disruption of the third apple domain structure of FXI. Furthermore, seven polymorphisms previously described, were also detected: C321F, c. 294A>G, -138 A>C, p.D125D, p.T249T, p.G379G, p.D551D. This report represents the first genetic study analyzing the molecular characteristics of factor XI deficiency within Tunisian population. Identification of the Jewish type II mutation in two families, as well as one missense previously reported mutation and one novel mutation confirmed the genetic heterogeneity of this disorder. Screening a large number of Tunisian factor XI deficient would reveal the spectrum mutations causing factor XI deficiency in Tunisia.

[1]  Chan Li,et al.  An update on factor XI structure and function. , 2018, Thrombosis research.

[2]  A. Folsom,et al.  Genome‐wide association study with additional genetic and post‐transcriptional analyses reveals novel regulators of plasma factor XI levels , 2017, Human molecular genetics.

[3]  K. Ghosh,et al.  Clinical and molecular epidemiology of factor XI deficiency in India. , 2016, Thrombosis research.

[4]  A. Guarini,et al.  Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  E. Keskin,et al.  Molecular basis and bleeding manifestations of factor XI deficiency in 11 Turkish families , 2015, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[6]  S. Duga,et al.  Congenital Factor XI Deficiency: An Update , 2013, Seminars in Thrombosis & Hemostasis.

[7]  H. Elmahmoudi,et al.  Regional registry of bleeding disorders in Tunisia , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  F. Rosendaal,et al.  Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders , 2012, Journal of thrombosis and haemostasis : JTH.

[9]  P. McEwan,et al.  Structure and function of factor XI. , 2010, Blood.

[10]  U. Seligsohn Factor XI deficiency in humans , 2009, Journal of thrombosis and haemostasis : JTH.

[11]  P. Morange,et al.  Prospective analysis of factor XI deficiencies in the Marseilles area identified four novel mutations among 12 consecutive unrelated families , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[12]  I. Guella,et al.  Factor XI deficiency in Southern Iran: identification of a novel missense mutation , 2009, Annals of Hematology.

[13]  P. Mannucci,et al.  Simultaneous genotyping of coagulation factor XI type II and type III mutations by multiplex real-time polymerase chain reaction to determine their prevalence in healthy and factor XI-deficient Italians , 2008, Haematologica.

[14]  U. Seligsohn,et al.  Factor XI in haemostasis and thrombosis: Past, present and future , 2007, Thrombosis and Haemostasis.

[15]  D. Steinberg,et al.  Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  D. Perry,et al.  Factor XI deficiency database: an interactive web database of mutations, phenotypes, and structural analysis tools , 2005, Human mutation.

[17]  M. Chandy,et al.  Novel missense mutations in two patients with factor XI deficiency (Val271Leu and Tyr351Ser) and one patient with combined factor XI and factor IX deficiency (Phe349Val) , 2005, Journal of thrombosis and haemostasis : JTH.

[18]  T. Dang,et al.  Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. , 2004, Blood.

[19]  N. O'Connell Factor XI deficiency--from molecular genetics to clinical management. , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[20]  D. Gailani,et al.  Identification of Amino Acids in the Factor XI Apple 3 Domain Required for Activation of Factor IX* , 1999, The Journal of Biological Chemistry.

[21]  M. Mittelman,et al.  The two common mutations causing factor XI deficiency in Jews stem from distinct founders: one of ancient Middle Eastern origin and another of more recent European origin. , 1997, Blood.

[22]  A. Chetrit,et al.  One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. , 1995, Blood.

[23]  E. Davie,et al.  Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. McCraw,et al.  Inheritance and bleeding in factor XI deficiency , 1988, British journal of haematology.